399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial

by Dean Harris, Daniel Brungs, Rahul Ladwah, Andrew Mant, Margaret McGrath, Andrea Tazbirkova, Andrey Akopov, Natalia Fadeeva, Boris Kasparov, Nadezhda Kovalenko, Vadim Kozlov, Fedor Moiseenko, Vasiliy Oschepkov, Piotr Koralewski, Dariusz Kowalski, Iwona Lugowska, Chaiyut Charoentumn, Arunee Dechaphunkul, Virote Sriuranpong, James Oliviero, Philip Clingan
Published 2020-11-01